Vincerx Pharma Inc
NASDAQ:VINC

Watchlist Manager
Vincerx Pharma Inc Logo
Vincerx Pharma Inc
NASDAQ:VINC
Watchlist
Price: 0.0125 USD Market Closed
Market Cap: 65.4k USD

Relative Value

There is not enough data to reliably calculate the relative value of VINC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VINC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-2.5
Industry
23.7
Forward
-0
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.7
Industry
22
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.7
Industry
24.3
vs History
93
vs Industry
78
Median 3Y
3.1
Median 5Y
4.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
0
vs Industry
26
Median 3Y
-1
Median 5Y
-1.7
Industry
6.1
vs History
0
vs Industry
24
Median 3Y
-1
Median 5Y
-1.7
Industry
6.5
Forward
0.2
vs History
0
vs Industry
28
Median 3Y
-1
Median 5Y
-1.8
Industry
7.9
vs History
0
vs Industry
24
Median 3Y
-1
Median 5Y
-1.8
Industry
6.3
vs History
vs Industry
36
Median 3Y
3.3
Median 5Y
0.7
Industry
5.7

Multiples Across Competitors

VINC Competitors Multiples
Vincerx Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vincerx Pharma Inc
NASDAQ:VINC
65.4k USD 0 -0 0.2 0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.7 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.2B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
153.6B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.4B USD 5.7 17.8 17 19.2
AU
CSL Ltd
ASX:CSL
83.5B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD 16.3 1 197.7 161.5 195.9
NL
argenx SE
XBRU:ARGX
43.6B EUR 14.2 33.5 57.7 59.2
P/S Multiple
Revenue Growth P/S to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average P/S: 3 369 303.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Vincerx Pharma Inc
NASDAQ:VINC
Average P/E: 189.5
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 197.7
N/A N/A
NL
argenx SE
XBRU:ARGX
33.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average EV/EBITDA: 35.5
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.5
N/A N/A
NL
argenx SE
XBRU:ARGX
57.7
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vincerx Pharma Inc
NASDAQ:VINC
Average EV/EBIT: 41
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59.2
N/A N/A